Introduction of New Whitepaper
We are excited to present our latest whitepaper, where we demonstrate the differentiation of iPSCs into hematopoietic stem progenitor cells (HSPCs) and subsequently into NKT cells using our “Synthetic Peptide Growth Factors,” also known as “PG-peptides”. These include VEGF (Vascular Endothelial Growth Factor), Wnt3a, and TPO (Thrombopoietin), which we’ve developed as PG-007, PG-008, and PG-010.
The development of iPSC-based cell therapy products typically relies on numerous growth factors that are often unstable, difficult to handle, and extremely expensive. These factors have posed significant hurdles in advancing iPSC-based therapies. Our synthetic peptide growth factors address these challenges with their stability, scalability, and cost-effectiveness, as they are chemically synthesized.
The application of PG-007, PG-008, and PG-010 in the differentiation of iPSCs into HSPCs and NKT cells has resulted in superior NKT cell productivity, providing another significant benefit of our PG-peptides. Download the whitepaper for full details on this application. We welcome your comments and questions, so please feel free to reach out to us!
Free Samples Available
We offer free samples of each product for your testing. Furthermore, if you could provide us feedback on your test results of our product samples, we will provide one more vial of our product for free! Please feel free to reach out to us regarding this sample testing program!
10 Products Now on Sale
We have launched 10 products so far (for more information, please visit our website). We would love to support your research and development, and we are happy to discuss the collaboration opportunities with members in MassBio.